;PMID: 3977942
;source_file_907.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..194] = [t:48..194]
;2)section:[e:198..220] = [t:198..220]
;3)sentence:[e:224..451] = [t:224..451]
;4)sentence:[e:452..501] = [t:452..501]
;5)sentence:[e:502..678] = [t:502..678]
;6)sentence:[e:679..771] = [t:679..771]
;7)sentence:[e:772..948] = [t:772..948]
;8)section:[e:952..996] = [t:952..996]
;Token/POS Errors
;ERROR_POS mismatch [33..34] t:token e:CD 5
;ERROR_POS mismatch [41..42] t:token e:. .
;ERROR_POS mismatch [995..996] t:token e:-RRB- ]

;section 0 Span:0..42
;Biochem Pharmacol. 1985 Mar 1;34(5):631-6.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1985) (NNP:[24..27] Mar) (CC:[28..30] 1;) (CD:[30..32] 34)
        (NNS:[32..33] -LRB-) (token:[33..34] 5) (-RRB-:[34..35] -RRB-)
        (::[35..36] :) (CD:[36..39] 631) (::[39..40] -) (CD:[40..41] 6)
        (token:[41..42] .)))

;sentence 1 Span:48..194
;Inhibition of rabbit nasal and hepatic cytochrome P-450-dependent 
;hexamethylphosphoramide (HMPA) N-demethylase by methylenedioxyphenyl
;compounds.
;[87..103]:cyp450:"cytochrome P-450"
;[115..159]:substance:"hexamethylphosphoramide (HMPA) N-demethylase"
;[163..193]:substance:"methylenedioxyphenyl compounds"
(SENT
  (NP-HLN
    (NP (NN:[48..58] Inhibition))
    (PP (IN:[59..61] of)
      (NP
        (NP
          (NML-1 (NN:[62..68] rabbit))
          (JJ:[69..74] nasal)
          (NML-2 (-NONE-:[74..74] *P*)))
        (CC:[75..78] and)
        (NP
          (NML-1 (-NONE-:[78..78] *P*))
          (JJ:[79..86] hepatic)
          (NML-2
            (ADJP
              (NML (NN:[87..97] cytochrome) (NN:[98..103] P-450))
              (HYPH:[103..104] -) (JJ:[104..113] dependent))
            
            (NML
              (NML (NN:[115..138] hexamethylphosphoramide))
              (NML (-LRB-:[139..140] -LRB-) (NN:[140..144] HMPA)
                   (-RRB-:[144..145] -RRB-)))
            (NN:[146..159] N-demethylase)))))
    (PP (IN:[160..162] by)
      (NP (NN:[163..183] methylenedioxyphenyl) (NNS:[184..193] compounds)))
    (.:[193..194] .)))

;section 2 Span:198..220
;Dahl AR, Brezinski DA.
(SEC
  (FRAG (NNP:[198..202] Dahl) (NNP:[203..205] AR) (,:[205..206] ,)
        (NNP:[207..216] Brezinski) (NNP:[217..219] DA) (.:[219..220] .)))

;sentence 3 Span:224..451
;Eighteen methylenedioxyphenyl (MDP) compounds, including some commonly
;inhaled  by people, were tested for the ability to inhibit rabbit nasal
;microsomal  cytochrome P-450-dependent hexamethylphosphoramide (HMPA)
;N-demethylase.
;[233..269]:substance:"methylenedioxyphenyl (MDP) compounds"
;[379..395]:cyp450:"cytochrome P-450"
;[406..450]:substance:"hexamethylphosphoramide (HMPA) N-demethylase"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[224..232] Eighteen)
        
        (NML
          (NML (NN:[233..253] methylenedioxyphenyl))
          (NML (-LRB-:[254..255] -LRB-) (NN:[255..258] MDP)
               (-RRB-:[258..259] -RRB-)))
        (NNS:[260..269] compounds))
      (,:[269..270] ,)
      (PP (VBG:[271..280] including)
        (NP
          (NP (DT:[281..285] some))
          (VP
            (ADVP (RB:[286..294] commonly))
            (VBN:[295..302] inhaled)
            (NP (-NONE-:[302..302] *))
            (PP (IN:[304..306] by)
              (NP-LGS (NNS:[307..313] people)))))))
    (,:[313..314] ,)
    (VP (VBD:[315..319] were)
      (VP (VBN:[320..326] tested)
        (NP-1 (-NONE-:[326..326] *))
        (PP (IN:[327..330] for)
          (NP (DT:[331..334] the) (NN:[335..342] ability)
            (S
              (NP-SBJ (-NONE-:[342..342] *))
              (VP (TO:[343..345] to)
                (VP (VB:[346..353] inhibit)
                  (NP (NN:[354..360] rabbit) (JJ:[361..366] nasal)
                      (JJ:[367..377] microsomal)
                    (ADJP
                      (NML (NN:[379..389] cytochrome) (NN:[390..395] P-450))
                      (HYPH:[395..396] -) (JJ:[396..405] dependent))
                    
                    (NML
                      (NML (NN:[406..429] hexamethylphosphoramide))
                      (NML (-LRB-:[430..431] -LRB-) (NN:[431..435] HMPA)
                           (-RRB-:[435..436] -RRB-)))
                    (NN:[437..450] N-demethylase)))))))))
    (.:[450..451] .)))

;sentence 4 Span:452..501
;For  comparison, liver microsomes were also used.
(SENT
  (S
    (PP (IN:[452..455] For)
      (NP (NN:[457..467] comparison)))
    (,:[467..468] ,)
    (NP-SBJ-1 (NN:[469..474] liver) (NNS:[475..485] microsomes))
    (VP (VBD:[486..490] were)
      (ADVP (RB:[491..495] also))
      (VP (VBN:[496..500] used)
        (NP-1 (-NONE-:[500..500] *))))
    (.:[500..501] .)))

;sentence 5 Span:502..678
;Nasal cytochrome P-450 from rabbits  metabolized MDP compounds to form
;cytochrome P-450-metabolite (P-450-MI)  complexes as indicated by difference
;spectra in the Soret region.
;[508..524]:cyp450:"cytochrome P-450"
;[551..564]:substance:"MDP compounds"
;[573..622]:substance:"cytochrome P-450-metabolite (P-450-MI)  complexes"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[502..507] Nasal)
         (NN:[508..518] cytochrome) (NN:[519..524] P-450))
      (PP (IN:[525..529] from)
        (NP (NNS:[530..537] rabbits))))
    (VP (VBD:[539..550] metabolized)
      (NP (NN:[551..554] MDP) (NNS:[555..564] compounds))
      (S-PRP
        (NP-SBJ (-NONE-:[564..564] *))
        (VP (TO:[565..567] to)
          (VP (VB:[568..572] form)
            (NP
              (NML
                (NML
                  (NML (NN:[573..583] cytochrome) (NN:[584..589] P-450))
                  (HYPH:[589..590] -) (NN:[590..600] metabolite))
                (NML (-LRB-:[601..602] -LRB-) (NN:[602..607] P-450)
                     (HYPH:[607..608] -) (NN:[608..610] MI)
                     (-RRB-:[610..611] -RRB-)))
              (NNS:[613..622] complexes)))))
      (SBAR-ADV (IN:[623..625] as)
        (S
          (NP-SBJ-1 (-NONE-:[625..625] *))
          (VP (VBN:[626..635] indicated)
            (NP-1 (-NONE-:[635..635] *))
            (PP (IN:[636..638] by)
              (NP-LGS
                (NP (NN:[639..649] difference) (NNS:[650..657] spectra))
                (PP-LOC (IN:[658..660] in)
                  (NP (DT:[661..664] the) (NNP:[665..670] Soret)
                      (NN:[671..677] region)))))))))
    (.:[677..678] .)))

;sentence 6 Span:679..771
;Several of the  MDP compounds were potent inhibitors of nasal P-450-dependent
;N-demethylase.
;[695..708]:substance:"MDP compounds"
;[721..731]:substance:"inhibitors"
;[741..746]:cyp450:"P-450"
;[757..770]:substance:"N-demethylase"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[679..686] Several))
      (PP (IN:[687..689] of)
        (NP (DT:[690..693] the)
           (NN:[695..698] MDP) (NNS:[699..708] compounds))))
    (VP (VBD:[709..713] were)
      (NP-PRD
        (NP (JJ:[714..720] potent) (NNS:[721..731] inhibitors))
        (PP (IN:[732..734] of)
          (NP (JJ:[735..740] nasal)
            (ADJP (NN:[741..746] P-450) (HYPH:[746..747] -)
                  (JJ:[747..756] dependent))
            (NN:[757..770] N-demethylase)))))
    (.:[770..771] .)))

;sentence 7 Span:772..948
;If  inhibition of nasal P-450 also occurs in vivo after inhibiting MDP
;compounds are  inhaled, the metabolism of concurrently or subsequently
;inhaled compounds may be  altered.
;[796..801]:cyp450:"P-450"
;[839..852]:substance:"MDP compounds"
;[922..931]:substance:"compounds"
(SENT
  (S
    (SBAR-ADV (IN:[772..774] If)
      (S
        (NP-SBJ
          (NP (NN:[776..786] inhibition))
          (PP (IN:[787..789] of)
            (NP (JJ:[790..795] nasal) (NN:[796..801] P-450))))
        (ADVP (RB:[802..806] also))
        (VP (VBZ:[807..813] occurs)
          (ADVP (FW:[814..816] in) (FW:[817..821] vivo))
          (SBAR-TMP (IN:[822..827] after)
            (S
              (NP-SBJ-2 (VBG:[828..838] inhibiting)
                 (NN:[839..842] MDP) (NNS:[843..852] compounds))
              (VP (VBP:[853..856] are)
                (VP (VBN:[858..865] inhaled)
                  (NP-2 (-NONE-:[865..865] *)))))))))
    (,:[865..866] ,)
    (NP-SBJ-3
      (NP (DT:[867..870] the) (NN:[871..881] metabolism))
      (PP (IN:[882..884] of)
        (NP
          (NP (RB:[885..897] concurrently)
            (NML-1 (-NONE-:[897..897] *P*)))
          (CC:[898..900] or)
          (NP (RB:[901..913] subsequently)
            (NML-1 (JJ:[914..921] inhaled) (NNS:[922..931] compounds))))))
    (VP (MD:[932..935] may)
      (VP (VB:[936..938] be)
        (VP (VBN:[940..947] altered)
          (NP-3 (-NONE-:[947..947] *)))))
    (.:[947..948] .)))

;section 8 Span:952..996
;PMID: 3977942 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[952..956] PMID) (::[956..957] :) (CD:[958..965] 3977942)
        (NN:[966..967] -LSB-) (NNP:[967..973] PubMed) (::[974..975] -)
        (NN:[976..983] indexed) (IN:[984..987] for) (NNP:[988..995] MEDLINE)
        (token:[995..996] -RSB-)))
